CytomX Therapeutics

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytomX Therapeutics reports robust financials and strategic pipeline advancements

CytomX Therapeutics showcased strong financial performance, with a focus on advancing key therapeutic programs and collaborations with industry partners. The company's strategic capital allocation supports pipeline development, while challenges include program prioritization and industry competition. Opportunities for growth exist in advancing pipeline milestones and leveraging collaborations for innovation.

CytomX reports robust Q1 earnings, advances pipeline with key partners

CytomX Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2023
The company's strategic collaborations and focus on innovation position it for future growth
Balancing expenses, regulatory milestones, and clinical progress are key challenges and opportunities
Overall, CytomX is well-positioned to drive value through its transformative therapies

CytomX advances pipeline and partnerships, poised for growth in oncology

CytomX Therapeutics demonstrated strong performance, financial stability, and strategic partnerships in Q2 2023, signaling a promising outlook for future growth.
The company's focus on localized therapies, leadership team strength, and diverse pipeline underscore its competitive position in the biopharmaceutical industry.
While facing challenges in a competitive landscape, CytomX has opportunities for growth through innovative programs, partnerships, and alignment with industry trends.

CytomX Therapeutics reports strong Q3 earnings and outlines strategic roadmap

CytomX Therapeutics showcased solid financial performance in Q3 2023 with revenue of $26.4 million and prudent cost management.
The company's focus on cancer medicines and pipeline advancements position it well for future growth and market competitiveness.
While facing challenges in data updates and cost balancing, strategic milestones and opportunities for collaborations offer avenues for expansion.
Overall, CytomX Therapeutics remains well-positioned in the oncology sector with a strong cash position and promising pipeline candidates.

CytomX posts robust Q4 results, poised for growth in 2024

CytomX Therapeutics delivered a strong performance in Q4 2023, showcasing financial stability, progress on its Probody platform, and strategic partnerships to drive innovation.
While facing challenges in clinical development and partnership dynamics, the company's strengths in product pipeline diversity and financial management offer a solid foundation for future growth.
With exciting opportunities ahead, including upcoming data readouts and advancements in immunotherapy, CytomX is well-positioned to capitalize on its expertise in antibody masking and conditional activation.

CytomX reports positive Phase Ia data for CX-904 therapy

CytomX Therapeutics showcases strong performance with promising drug data.
Company's financial stability and innovative platform position it well for growth.
Challenges in translating research to clinical outcomes and predicting patient responses.
Opportunities lie in expanding drug potential, exploring combination strategies, and addressing assay challenges.

CytomX reports strong Q3 results, advances promising oncology therapies

CytomX Therapeutics delivered solid financial performance in Q3 2024 with a focus on key oncology programs.
The company's Probody platform shows promise in addressing unmet medical needs in various cancers.
Challenges lie in optimizing dose escalation, enrollment, and expansion of therapies to maximize impact.
Strategic partnerships and disciplined capital allocation position CytomX for future growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors.

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CytomX Therapeutics (NASDAQ: CTMX ) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report. The CytomX Therapeutics earnings report notes that the company spent most of 2023 cutting costs to continue operations.

Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today?

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Joe Catanzaro - Piper Sandler Malcolm Kuno - JPMorgan Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial Results Conference Call.

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.42 per share a year ago.

CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 -

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2023 financial results on Monday, March 11, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.

CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in March.

CytomX Therapeutics to Present at Upcoming March Investor Conferences

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a fireside chat at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 18, 2024 at 1:00 p.m. ET.

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in  the 2 nd half of 2024 -

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 p.m. PT.

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: What Does It Mean for the Stock?

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Roger Song - Jefferies. Jade Montgomery - H.C.

CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 -

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in November.

CytomX Therapeutics to Present at Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report third quarter financial results on Tuesday, November 7, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

- IND filing for CX-801 anticipated by the end of 2023 - SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that preclinical data supporting CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California.

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload -

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September.

CytomX Therapeutics to Present at Upcoming September Investor Conferences

The heavy selling pressure might have exhausted for CytomX Therapeutics (CTMX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C. Wainwright Immune Cell Engager Virtual Conference on Thursday, August 17 at 9:00 a.m. ET.

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2023 Results Conference Call August 8, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer Conference Call Participants Roger Song - Jefferies Depeche Patel - H.C. Wainwright Operator Good day, and welcome to the CytomX Therapeutics Second Quarter 2023 Financial Results Conference Call.

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.37 per share a year ago.

News for CytomX Therapeutics Stock (CTMX)